{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:04:54Z","timestamp":1779800694348,"version":"3.53.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00105-026-05681-7","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:22:51Z","timestamp":1776417771000},"page":"388-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Etablierte und innovative Behandlungsans\u00e4tze in der Berufsdermatologie","Traditional and innovative treatment approaches in occupational dermatology"],"prefix":"10.1007","volume":"77","author":[{"given":"Lara","family":"Obermeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Skudlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"5681_CR1","unstructured":"Awmf S3-Leitlinie \u201eTherapie der Psoriasis vulgaris\u201c (AWMF-Reg.-Nr. 013-001) | Appendix A \u201eTopische Therapie, Phototherapie, Sonstige Therapien, Schnittstellendefinition\u201c Fortbestand der Empfehlungen vom Update 2015."},{"key":"5681_CR2","first-page":"1054","volume":"21","author":"A Bauer","year":"2023","unstructured":"Bauer\u00a0A, Brans\u00a0R, Brehler\u00a0R et\u00a0al (2023) S2k-Leitlinie Diagnostik, Pravention und Therapie des Handekzems: S2k guideline diagnosis, prevention and therapy of hand eczema. J\u00a0Dtsch Dermatol Ges 21:1054\u20131076","journal-title":"J Dtsch Dermatol Ges"},{"key":"5681_CR3","unstructured":"Dguv (2015) RS 0170\/2015 vom 21.04.2015 Basistherapie im Hautarztverfahren, Sachgebiet(e): Berufskrankheiten."},{"key":"5681_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40629-023-00246-9","volume":"32","author":"H Dickel","year":"2023","unstructured":"Dickel\u00a0H (2023) Management of contact dermatitis. Allergo Journal International 32:57\u201376","journal-title":"Allergo Journal International"},{"key":"5681_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/ddg.14734_g","volume":"20","author":"H Dickel","year":"2022","unstructured":"Dickel\u00a0H, Bauer\u00a0A, Brehler\u00a0R et\u00a0al (2022) S1-Leitlinie Kontaktekzem. J\u00a0Dtsch Dermatol Ges 20:711\u2013734","journal-title":"J Dtsch Dermatol Ges"},{"key":"5681_CR6","unstructured":"Ema European Medicines Agency. Cibinqo : EPAR \u2013 Product information. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf [Last accessed on January\u00a07, 2026]. ."},{"key":"5681_CR7","unstructured":"Ema European Medicines Agency. Olumiant : EPAR \u2013 Product information. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf [Last accessed January\u00a07, 2026]."},{"key":"5681_CR8","unstructured":"Ema European Medicines Agency. Rinvoq : EPAR \u2013 Product information. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf [Last accessed on January\u00a07, 2026]."},{"key":"5681_CR9","unstructured":"Fachinfo Anzupgo\u00ae 20\u202fmg\/g Creme"},{"key":"5681_CR10","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1096\/fasebj.10.9.8801161","volume":"10","author":"GJ Fisher","year":"1996","unstructured":"Fisher\u00a0GJ, Voorhees\u00a0JJ (1996) Molecular mechanisms of retinoid actions in skin. FASEB\u00a0J 10:1002\u20131013","journal-title":"FASEB J"},{"key":"5681_CR11","volume-title":"Richtig verschreiben \u2013 individuell therapieren","author":"C Garbe","year":"2023","unstructured":"Garbe\u00a0C, Reimann\u00a0H (2023) Dermatologische Rezepturen. In: Richtig verschreiben \u2013 individuell therapieren. Georg Thieme Verlag KG, Stuttgart"},{"key":"5681_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/cod.14276","volume":"88","author":"E Kamphuis","year":"2023","unstructured":"Kamphuis\u00a0E, Loman\u00a0L, Han\u00a0HL et\u00a0al (2023) Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Contact Dermatitis 88:351\u2013362","journal-title":"Contact Dermatitis"},{"key":"5681_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000481545","volume":"31","author":"A Kramer","year":"2018","unstructured":"Kramer\u00a0A, Dissemond\u00a0J, Kim\u00a0S et\u00a0al (2018) Consensus on Wound Antisepsis: Update 2018. Skin Pharmacol Physiol 31:28\u201358","journal-title":"Skin Pharmacol Physiol"},{"key":"5681_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5414\/DBX00462","volume":"71","author":"S Krohn","year":"2023","unstructured":"Krohn\u00a0S, Skudlik\u00a0C, Bauer\u00a0A et\u00a0al (2023) Therapieformen bei der Behandlung von Berufsdermatosen der BK-Nr. 5101. Begriffsdefinitionen f\u00fcr die Praxis der gesetzlichen Unfallversicherung. Dermatologie in Beruf und Umwelt 71:137\u2013145","journal-title":"Dermatologie in Beruf und Umwelt"},{"key":"5681_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/ajd.14074","volume":"64","author":"SD Lee","year":"2023","unstructured":"Lee\u00a0SD, Ahn\u00a0HJ, Shin\u00a0MK (2023) Nine cases of chronic hand and foot eczema treated with baricitinib. Australas J Dermatol 64:408\u2013412","journal-title":"Australas J Dermatol"},{"key":"5681_CR16","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.39822","volume":"104","author":"Y Li","year":"2024","unstructured":"Li\u00a0Y, Tan\u00a0X, Nie\u00a0S et\u00a0al (2024) Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients. Acta Derm Venereol 104:adv39822","journal-title":"Acta Derm Venereol"},{"key":"5681_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1046\/j.1439-0353.2004.03626.x","volume":"2","author":"T Luger","year":"2004","unstructured":"Luger\u00a0T (2004) Topische Dermatotherapie mit Glukokortikoiden \u2013 Therapeutischer Index. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2:629\u2013634","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"5681_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13671-013-0062-x","volume":"2","author":"I Malka","year":"2013","unstructured":"Malka\u00a0I, Ziv\u00a0M (2013) Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women. Current Dermatology Reports 2:249\u2013257","journal-title":"Current Dermatology Reports"},{"key":"5681_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/cod.13883","volume":"85","author":"L Obermeyer","year":"2021","unstructured":"Obermeyer\u00a0L, Skudlik\u00a0C, John\u00a0SM et\u00a0al (2021) Treatment with alitretinoin in patients taking part in a tertiary individual prevention program for work-related skin diseases. Contact Dermatitis 85:446\u2013453","journal-title":"Contact Dermatitis"},{"key":"5681_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/cod.14775","volume":"92","author":"D Pesqu\u00e9","year":"2025","unstructured":"Pesqu\u00e9\u00a0D, Silvestre-Salvador\u00a0JF, Figueiredo\u00a0AC et\u00a0al (2025) A Review of Hand Eczema Subtypes: Clinical Features, Biomarkers and Treatment Strategies. Contact Dermatitis 92:421\u2013435","journal-title":"Contact Dermatitis"},{"key":"5681_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/jid.2009.389","volume":"130","author":"JH Roelofzen","year":"2010","unstructured":"Roelofzen\u00a0JH, Aben\u00a0KK, Oldenhof\u00a0UT et\u00a0al (2010) No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J\u00a0Invest Dermatol 130:953\u2013961","journal-title":"J Invest Dermatol"},{"key":"5681_CR22","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1111\/jdv.19194","volume":"37","author":"EL Simpson","year":"2023","unstructured":"Simpson\u00a0EL, Rahawi\u00a0K, Hu\u00a0X et\u00a0al (2023) Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials. J\u00a0Eur Acad Dermatol Venereol 37:1863\u20131870","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5681_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaad.2023.12.066","volume":"90","author":"EL Simpson","year":"2024","unstructured":"Simpson\u00a0EL, Silverberg\u00a0JI, Worm\u00a0M et\u00a0al (2024) Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J\u00a0Am Acad Dermatol 90:1190\u20131199","journal-title":"J Am Acad Dermatol"},{"key":"5681_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5414\/DBX0271","volume":"64","author":"C Skudlik","year":"2016","unstructured":"Skudlik\u00a0C, Kagel\u00a0V, M\u00e4hlhop\u00a0C et\u00a0al (2016) Empfehlung zur Durchf\u00fchrung einer PUVA-Heimtherapie als Ausnahmeregel im BG-lichen Heilverfahren. Dermatologie in Beruf und Umwelt 64:166\u2013171","journal-title":"Dermatologie in Beruf und Umwelt"},{"key":"5681_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00105-013-2592-3","volume":"64","author":"C Skudlik","year":"2013","unstructured":"Skudlik\u00a0C, Lindemann\u00a0B, Woltjen\u00a0M et\u00a0al (2013) \u201cWith all suitable means\u201d. Off-label-use and public statutory employers\u2019 liability insurance. Hautarzt 64:743\u2013747","journal-title":"Hautarzt"},{"key":"5681_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-50518-2","volume-title":"Berufsdermatologie","author":"C Skudlik","year":"2023","unstructured":"Skudlik\u00a0C, Sch\u00f6n\u00a0MP, John\u00a0SM (2023) Berufsdermatologie. Springer Verlag"},{"key":"5681_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00105-017-4033-1","volume":"68","author":"P Staubach","year":"2017","unstructured":"Staubach\u00a0P, Melhorn\u00a0S (2017) Topical antiseptic agents. Hautarzt 68:835\u2013851","journal-title":"Hautarzt"},{"key":"5681_CR28","first-page":"955","volume":"26","author":"F Wang","year":"2012","unstructured":"Wang\u00a0F, Yuan\u00a0N, Wang\u00a0Y et\u00a0al (2012) Clinical study on topical bismuth subgallate\/borneol (Suile) dressing for treatment of diabetic foot ulcers. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 26:955\u2013960","journal-title":"Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi"},{"key":"5681_CR29","first-page":"137","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel\u00a0T, Heratizadeh\u00a0A, Aberer\u00a0W et\u00a0al (2024) S3-Leitlinie Atopische Dermatitis: Teil 1\u2011 Allgemeine Aspekte, topische und nichtmedikament\u00f6se Therapien, besondere Patientengruppen. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 22:137\u2013155","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"5681_CR30","first-page":"307","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel\u00a0T, Heratizadeh\u00a0A, Aberer\u00a0W et\u00a0al (2024) S3-Leitlinie Atopische Dermatitis: Teil 2 - Systemische Therapie. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 22:307\u2013322","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"5681_CR31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.18469","volume":"182","author":"M Worm","year":"2020","unstructured":"Worm\u00a0M, Bauer\u00a0A, Elsner\u00a0P et\u00a0al (2020) Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol 182:1103\u20131110","journal-title":"Br J Dermatol"},{"key":"5681_CR32","first-page":"1265","volume":"19","author":"PC Wu","year":"2021","unstructured":"Wu\u00a0PC, Huang\u00a0IH, Liu\u00a0CW et\u00a0al (2021) Topische Calcineurininhibitoren und das Risiko fur Lymphome: eine systematische Ubersicht und Metaanalyse. J\u00a0Dtsch Dermatol Ges 19:1265\u20131270","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05681-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:25:25Z","timestamp":1779798325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05681-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5681"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05681-7","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Obermeyer: Vortrags- und Beratert\u00e4tigkeit (Fa. LEO Pharma, Fa. Galderma). C.\u00a0Skudlik: Vortrags- und Beratert\u00e4tigkeit (Fa. Almirall, Fa. Beiersdorf\/Eucerin, Fa. Biofrontera, Fa. Dr. Wolff Group, Fa. Galderma Laboratorium, Fa. LEO Pharma, Fa. L\u2019Or\u00e8al\/CeraVe, Fa. Pierre Fabre Dermo-Kosmetik, Fa. Sanofi-Aventis).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}